

**Reviewer A**

I read with great interest the Manuscript titled “A novel machine learning-driven immunogenic cell death signature for predicting ovarian cancer prognosis”, topic interesting enough to attract readers' attention.

Although the manuscript can be considered already of good quality, I would suggest following recommendations:

- In last years various mutations had been detected and several molecular inhibitors have been developed for the treatment of ovarian cancer, whose antitumor potential is currently being assessed in different clinical trials. Considering results and topic of this study, I suggest reading and adding recent references referring to PMID: 38768941

Reply 1: Thank you for your advice. We added relevant citations.

Changes in the text: see Page 4, line 102.

- Growing evidence has demonstrated the role of mutations of tumor biomarkers in diagnosing and management of ovarian cancer. I suggest analyzing recent literature on the correlation between tumor biomarkers and chemotherapy in ovarian cancer, providing suggestions for personalized treatment approaches. I suggest reading and adding recent references referring to PMID: 39457020

Reply 2: Thank you for your advice. We added relevant citations.

Changes in the text: see Page 4, line 102.

Because of these reasons, the article should be revised and completed. Considering all these points, I think it could be of interest to the readers and, in my opinion, it deserves the priority to be published after minor revisions.

**Reviewer B**

**1. Figure 2**


Please explain “\*\*\*” in figure legend.

Reply: Thank you for your advice. We have explained “\*\*\*” in figure legend.

Changes in the text: see Page 15, line 485-494.

**2. Figure 3**

Please indicate the description of X-axis.



Reply: Thank you for your advice. We have indicated the description of X-axis.  
Changes in the text: see Page 15, line 497-498.

### 3. Figure 4


a. It is “P<0.0001” in figure 4A-C. Please unify.

314 coefficients from the Cox regression, with patients being classified into high- and  
315 low-risk groups based on the median score. The Kaplan-Meier survival method then  
316 demonstrated a significant decrease in OS for high-risk patients within the training set  
317 (TCGA-OC; P<0.001; Figure 4A) and in the validation sets, including the test set  
318 (P<0.001; Figure 4B), the combined set (P<0.001; Figure 4C), and the GSE73614

Reply: Thank you for your advice. We have unified them.

Changes in the text: see Page 10, line 316-317.

b. Please revise “1 year, 3 year, 5 year” to “1-year, 3-year, 5-year” or “1 year, 3 years, 5 years” in Figure 4 (I-L).




Reply: Thank you for your advice. We made changes as requested.

### 4. Figure 5

a. Please revise “Hazard ratio” to “Hazard ratio (95% CI)”.


Reply: Thank you for your advice. We made changes as requested.

b. To standardize the results, the part that exceeds the horizontal coordinates should be indicated by arrows, or please extend the X-axis.



Reply: Thank you for your advice. We made changes as requested.

c. Please indicate the unit of age.



Reply: Thank you for your advice. We indicated the unit of aged.

**5. Figure 6 is a (A-D) combined picture, while legend (E) was mentioned. Please check and revise.**

Reply: Thank you for your advice. We made changes as requested.  
Changes in the text: see Page 16, line 519.

**6. Figure 7**

a. Please explain (\*, ns) in figure legend.



Reply: Thank you for your advice. We made changes as requested.  
Changes in the text: see Page 16, line 524-525.

b. Please indicate the description of these Y-axis and X-axis in figure 7B.

Reply: Thank you for your advice. We indicated the description of these Y-axis and X-axis.

Changes in the text: see Page 16, line 526-528.

**7. Figure 8**

a. Please explain (\*\*, \*\*\*) in figure legend.

Reply: Thank you for your advice. We made changes as requested.  
Changes in the text: see Page 16, line 534-535.

b. It is “AZD2014” in figure, while it is “osimertinib” in figure legend. Please check which one is correct.

Reply: Thank you for your advice. We changed “AZD2014” to “Vistusertib”.  
Changes in the text: see Page 13, line 428.